Patents by Inventor Harry H. Zhabilov

Harry H. Zhabilov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Irreversibly-inactivated pepsinogen fragments for modulating immune function
    Patent number: 8309072
    Abstract: Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG (SEQ ID NO: 1); TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP (SEQ ID NO: 2); CCATSGPCGAVMILTPHLTA (SEQ ID NO: 5); MTLTTGSGAIAPAMPPGLPPHTGAIHAPM (SEQ ID NO: 4); and NXVPVSVEGYXQITLDSITX (SEQ ID NO: 3) and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide characterized by the amino acid sequence GDEPLENYLDTEYF (SEQ ID NO: 6) and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: November 13, 2012
    Assignee: The Zhabilov Trust
    Inventor: Harry H. Zhabilov
  • Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing and treating HIV
    Patent number: 8066982
    Abstract: An isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41 and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: November 29, 2011
    Assignee: The Zhabilov Trust
    Inventor: Harry H. Zhabilov
  • Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells
    Patent number: 8067531
    Abstract: Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG; TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP; CCATSGPCGAVMILTPHLTA; MTLTTGSGAIAPAMPPGLPPHTGAIHAPM; and NXVPVSVEGYXQITLDSITX and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: November 29, 2011
    Assignee: The Zhabilov Trust
    Inventor: Harry H. Zhabilov
  • Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing and treating HIV
    Publication number: 20100204133
    Abstract: An isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41 and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.
    Type: Application
    Filed: January 16, 2009
    Publication date: August 12, 2010
    Inventor: Harry H. Zhabilov
  • Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells
    Publication number: 20100143291
    Abstract: Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG; TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP; CCATSGPCGAVMILTPHLTA; MTLTTGSGAIAPAMPPGLPPHTGAIHAPM; and NXVPVSVEGYXQITLDSITX and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.
    Type: Application
    Filed: December 2, 2008
    Publication date: June 10, 2010
    Inventor: Harry H. Zhabilov
  • Antiviral compositions comprising lysine-rich histone fractions prepared by pepsin treatment of thymic cell nuclei
    Patent number: 7625565
    Abstract: This invention relates to the area of immunology and virology, and specifically relates to compositions obtainable from mammalian thymus cells which are useful as diagnostics, vaccines, and therapeutics for human immunodeficiency virus (HIV) infection and related diseases such as acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). The diagnostic, vaccination, and therapeutic methods, and devices, using these compositions are also disclosed.
    Type: Grant
    Filed: January 3, 2003
    Date of Patent: December 1, 2009
    Assignee: Viral Genetics, Inc.
    Inventors: Harry P. Zhabilov, Jordanka Zhabilov, legal representative, Harry H. Zhabilov
  • IRREVERSIBLY-INACTIVATED PEPSINOGEN FRAGMENTS FOR MODULATING IMMUNE FUNCTION
    Publication number: 20090285776
    Abstract: Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG; TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP; CCATSGPCGAVMILTPHLTA; MTLTTGSGAIAPAMPPGLPPHTGAIHAPM; and NXVPVSVEGYXQITLDSITX and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.
    Type: Application
    Filed: June 18, 2009
    Publication date: November 19, 2009
    Inventor: Harry H. Zhabilov
  • Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing, and treating HIV
    Patent number: 7479538
    Abstract: An isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.
    Type: Grant
    Filed: July 11, 2005
    Date of Patent: January 20, 2009
    Assignee: The Zhabilov Trust
    Inventor: Harry H. Zhabilov